For the Inventor, By the Inventor

Enter assignee name

Baltimore, MD, United States of America

Lupin, Inc.

USPTO Granted Patents = 157

CIPO Patents = 7

EPO Patents = 46

Trademarks = 27

Forward Citations = 230

Loading Chart...

Loading Chart...

335 inventors (with patents filed for the assignee):

Rajender Kumar Kamboj (42 out of 46 patents)

Venkata Poornapragnacharyulu Palle (37 out of 104 patents)

Girij Pal Singh (31 out of 32 patents)

4. Neelima Sinha (22 out of 31 patents)

5. Shirishkumar Kulkarni (13 out of 14 patents)

6. Navnath Popat Karche (11 out of 11 patents)

7. David Palling (10 out of 15 patents)

8. Helen S Pentikis (9 out of 10 patents)

9. Carol J Braun (9 out of 10 patents)

10. Makarand Krishnakumar Avachat (9 out of 9 patents)

11. Richard Holl (8 out of 8 patents)

12. Harshal Jahagirdar (8 out of 8 patents)

13. Sanjeev Anant Kulkarni (8 out of 15 patents)

14. Anil Kashiram Hajare (8 out of 8 patents)

15. Himanshu Madhav Godbole (8 out of 9 patents)

Core Competencies:

Macrocyclic Compounds

PRMT5 Inhibitors

Chromans

Implantable Drug Delivery

Secnidazole

Inhalers

Modified Release Formulation

HIV Integrase Inhibitors

Cysteamine Bitartrate

Oxazoline Derivatives

Pharmaceutical Compositions

Voltage-Gated Sodium Channel Modulators

157 patents: Sort by Forward Citations

1. 12479858 - Macrocyclic compounds as sting agonists and methods and uses thereof (2025-11-25),

2. 12465565 - Pharmaceutical compositions of raltegravir (2025-11-11),

3. 12447152 - Pharmaceutical combination of PRMT5 inhibitors (2025-10-21),

4. 12435066 - Substituted tricyclic compounds (2025-10-07),

5. 12421204 - Process for preparing chroman compounds (2025-09-23),

6. 12391695 - PRMT5 inhibitors (2025-08-19),

7. D1085407 - Applicator for implantable drug delivery (2025-07-22),

8. D1085406 - Applicator for implantable drug delivery (2025-07-22),

9. 12344592 - Methods, processes and intermediates for preparing chroman compounds (2025-07-01),

10. D1058364 - Tray (2025-01-21),

11. 12124920 - Event status apparatuses and related devices, systems, and methods (2024-10-22),

12. 11952380 - Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors (2024-04-09),

13. 11684607 - Secnidazole for use in the treatment of bacterial vaginosis (2023-06-27),

14. D984631 - Inhaler (2023-04-25),

15. 11602522 - Secnidazole for use in the treatment of sexually transmitted infection (2023-03-14),

Lupin, Inc. is a global pharmaceutical company that focuses on generic and branded drugs. With headquarters in Mumbai, India, Lupin operates in over 100 countries. The company's mission is to bring high-quality and affordable healthcare solutions to people worldwide. Lupin has a diverse product portfolio covering therapeutic areas such as cardiovascular, diabetes, respiratory, immunology, and more. Committed to research and development, Lupin invests in innovative drug discovery and development programs to address unmet medical needs.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

157 Patents

#3 in Baltimore, MD

#15 in Maryland

#2,445 in US

#5,100 in the World

Baltimore, MD, United States of America

Lupin, Inc.

Forward Citations = 230

335 inventors:

Rajender Kumar Kamboj (42 out of 46 patents)

Venkata Poornapragnacharyulu Palle (37 out of 104 patents)

Girij Pal Singh (31 out of 32 patents)

4. Neelima Sinha (22 out of 31 patents)

5. Shirishkumar Kulkarni (13 out of 14 patents)

Please report any incorrect information to support@idiyas.com

Loading…